On October 19, HTA Co Ltd, a subsidiary of China Isotope & Radiation Corporation (CIRC) under CNNC, held high-level talks with the International Atomic Energy Agency (IAEA) in Vienna, Austria. The two sides signed a Practical Arrangement to support the IAEA's Rays of Hope initiative in nuclear medicine and radiopharmaceuticals.

Under the arrangement, both parties will strengthen capacity building through professional training, scientific visits, expert missions, and technical meetings. They will also deepen knowledge exchange in the research and development, production, quality management, distribution, and clinical application of medical isotopes and radiopharmaceuticals, helping advance their use in cancer diagnosis, staging, treatment planning, treatment, and follow-up care.

Cancer remains a major public health challenge worldwide. HTA strongly supports the mission and goals of the Rays of Hope initiative. With long-standing expertise in the research, production, and application of medical isotopes and radiopharmaceuticals for diagnostic and therapeutic purposes, the company has built extensive experience in quality management, reliable supply, and comprehensive nuclear medicine services.

The signing marks a new phase of cooperation that is more structured, systematic, and pragmatic. HTA will actively contribute its expertise to turn the shared commitment into lasting results, helping bring the benefits of nuclear technology to more people worldwide.